공시 • Apr 16
Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic Crops Amoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation. Price Target Changed • Apr 14
Price target decreased by 15% to €1.10 Down from €1.30, the current price target is provided by 1 analyst. New target price is 29% above last closing price of €0.86. Stock is down 12% over the past year. The company is forecast to post a net loss per share of €0.075 next year compared to a net loss per share of €0.14 last year. 공시 • Mar 26
Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,333,333
Price\Range: €0.75
Transaction Features: Subsequent Direct Listing New Risk • Mar 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€63.4m market cap, or US$73.5m). Breakeven Date Change • Sep 04
Forecast to breakeven in 2027 The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule. New Risk • Jul 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m). 
